In Situ photoimmunotherapy for advanced cutaneous melanoma

Mark F. Naylor, Robert E. Nordquist, T. Kent Teaque, David Adelson, Lisa A. Perry, Wei R. Chen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.

Original languageEnglish (US)
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume6857
DOIs
StatePublished - 2008
Externally publishedYes
EventBiophotonics and Immune Responses III - San Jose, CA, United States
Duration: Jan 21 2008Jan 21 2008

Other

OtherBiophotonics and Immune Responses III
CountryUnited States
CitySan Jose, CA
Period1/21/081/21/08

Fingerprint

Lasers

Keywords

  • Imiquimod
  • Immunotherapy
  • Laser
  • Melanoma
  • Solid tumor therapy

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Naylor, M. F., Nordquist, R. E., Teaque, T. K., Adelson, D., Perry, L. A., & Chen, W. R. (2008). In Situ photoimmunotherapy for advanced cutaneous melanoma. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 6857). [685702] https://doi.org/10.1117/12.764970

In Situ photoimmunotherapy for advanced cutaneous melanoma. / Naylor, Mark F.; Nordquist, Robert E.; Teaque, T. Kent; Adelson, David; Perry, Lisa A.; Chen, Wei R.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6857 2008. 685702.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Naylor, MF, Nordquist, RE, Teaque, TK, Adelson, D, Perry, LA & Chen, WR 2008, In Situ photoimmunotherapy for advanced cutaneous melanoma. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 6857, 685702, Biophotonics and Immune Responses III, San Jose, CA, United States, 1/21/08. https://doi.org/10.1117/12.764970
Naylor MF, Nordquist RE, Teaque TK, Adelson D, Perry LA, Chen WR. In Situ photoimmunotherapy for advanced cutaneous melanoma. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6857. 2008. 685702 https://doi.org/10.1117/12.764970
Naylor, Mark F. ; Nordquist, Robert E. ; Teaque, T. Kent ; Adelson, David ; Perry, Lisa A. ; Chen, Wei R. / In Situ photoimmunotherapy for advanced cutaneous melanoma. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6857 2008.
@inproceedings{f1fe56be82bc48228ca8e3ba62deb327,
title = "In Situ photoimmunotherapy for advanced cutaneous melanoma",
abstract = "Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.",
keywords = "Imiquimod, Immunotherapy, Laser, Melanoma, Solid tumor therapy",
author = "Naylor, {Mark F.} and Nordquist, {Robert E.} and Teaque, {T. Kent} and David Adelson and Perry, {Lisa A.} and Chen, {Wei R.}",
year = "2008",
doi = "10.1117/12.764970",
language = "English (US)",
isbn = "9780819470324",
volume = "6857",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

}

TY - GEN

T1 - In Situ photoimmunotherapy for advanced cutaneous melanoma

AU - Naylor, Mark F.

AU - Nordquist, Robert E.

AU - Teaque, T. Kent

AU - Adelson, David

AU - Perry, Lisa A.

AU - Chen, Wei R.

PY - 2008

Y1 - 2008

N2 - Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.

AB - Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.

KW - Imiquimod

KW - Immunotherapy

KW - Laser

KW - Melanoma

KW - Solid tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=43249099816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249099816&partnerID=8YFLogxK

U2 - 10.1117/12.764970

DO - 10.1117/12.764970

M3 - Conference contribution

SN - 9780819470324

VL - 6857

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

ER -